In a Phase 1 Cleveland Clinic trial, a single infusion of an experimental gene editing therapy called CTX310 cut bad LDL cholesterol by over 50 per cent for a full year.

By using CRISPR technology to deactivate the ANGPTL3 gene in the liver, the single-dose treatment also reduced triglycerides by 47.8 per cent.